Style | Citing Format |
---|---|
MLA | Saiyarsarai P, et al.. "A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis." Medicine (United States), vol. 100, no. 40, 2021, pp. E27303-. |
APA | Saiyarsarai P, Robabpour Derakhshan A, Khedmati J, Eshghi P, Seyedifar M (2021). A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis. Medicine (United States), 100(40), E27303-. |
Chicago | Saiyarsarai P, Robabpour Derakhshan A, Khedmati J, Eshghi P, Seyedifar M. "A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis." Medicine (United States) 100, no. 40 (2021): E27303-. |
Harvard | Saiyarsarai P et al. (2021) 'A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis', Medicine (United States), 100(40), pp. E27303-. |
Vancouver | Saiyarsarai P, Robabpour Derakhshan A, Khedmati J, Eshghi P, Seyedifar M. A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis. Medicine (United States). 2021;100(40):E27303-. |
BibTex | @article{ author = {Saiyarsarai P and Robabpour Derakhshan A and Khedmati J and Eshghi P and Seyedifar M}, title = {A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis}, journal = {Medicine (United States)}, volume = {100}, number = {40}, pages = {E27303-}, year = {2021} } |
RIS | TY - JOUR AU - Saiyarsarai P AU - Robabpour Derakhshan A AU - Khedmati J AU - Eshghi P AU - Seyedifar M TI - A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis JO - Medicine (United States) VL - 100 IS - 40 SP - E27303 EP - PY - 2021 ER - |